Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Total Liabilities (2016 - 2025)

Regenxbio has reported Total Liabilities over the past 12 years, most recently at $350.3 million for Q4 2025.

  • Quarterly results put Total Liabilities at $350.3 million for Q4 2025, up 69.77% from a year ago — trailing twelve months through Dec 2025 was $350.3 million (up 69.77% YoY), and the annual figure for FY2025 was $350.3 million, up 69.77%.
  • Total Liabilities for Q4 2025 was $350.3 million at Regenxbio, down from $363.8 million in the prior quarter.
  • Over the last five years, Total Liabilities for RGNX hit a ceiling of $367.3 million in Q2 2025 and a floor of $206.3 million in Q4 2024.
  • Median Total Liabilities over the past 5 years was $318.5 million (2022), compared with a mean of $295.6 million.
  • Biggest five-year swings in Total Liabilities: surged 642.14% in 2021 and later dropped 21.31% in 2024.
  • Regenxbio's Total Liabilities stood at $349.6 million in 2021, then dropped by 9.31% to $317.1 million in 2022, then decreased by 17.3% to $262.2 million in 2023, then dropped by 21.31% to $206.3 million in 2024, then skyrocketed by 69.77% to $350.3 million in 2025.
  • The last three reported values for Total Liabilities were $350.3 million (Q4 2025), $363.8 million (Q3 2025), and $367.3 million (Q2 2025) per Business Quant data.